This is wonderful news for 534, and at the very least , confirms what Harv has been saying all year. Finally, Gleevec, Sprycel and Tasigna will go head to head in first line CML treatment, which means that 534 has a clearer path to 2nd line treatment. I am not a scientist, but it appears to me that if all three compete for first line then it creates a larger pie for a new 2nd line treatment drug (534) because if patients mutate on either Tasigna or Sprycel, 2nd line market expands. I would appreciate some feedback drom the scientists on the board as to whether what I said makes any sense, or am I just showing my scientific ignorance. I also remember that one of the scientists that created Gleevec, and was also involved in the phase 1 534 clinical trial, stated that 534 was ten (10) times more potent than Gleevec. I also recall another Dr., who was involved in the 534 trial,and is one of the leading CML treating physician and experts in the world, as stating that 534 was a "super" Gleevec and he believed that it may even prevent some of the CML mutations from occuring, or at least stalling them off for a longer period of time. Does this all mean that, assuming 534 meets it's primary endpoints in the current pivotal trial, that we might be looking, in the future, at a first line treatment for CML? Looking forward to responses from our scientist members.
As usual, JMHO
News 
Market Data 
Discover 
